Number of South Korean biotech sites increased by 12% last year: Novotech

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/HStocks)
(Image: Getty/HStocks)

Related tags: Novotech, South korea, CRO, Contract research

The Asia-Pacific CRO Novotech has grown its operations in South Korea, a market that has seen greater interest from North American and European companies, says exec.

The contract research organization (CRO) has 10 strategic collaborations with hospitals and research institutions in the area and increased its clinical staff to 41 over the last 12 months.

“Novotech staff in South Korea has grown by about 40% compared with last year, which represents one of the fastest growth for a CRO in the country, and reflect the increase clinical trial demand in the country,” ​said Yooni Kim, Novotech executive director, Asia operations.

According to the company – which now has 41 clinical staff members at its center in South Korea –  recent regulatory changes have facilitated study start-up, with the Ministry of Food and Drug Safety (MFDS) and ethics committee (EC) approvals now taking just over two months on average.

Additionally, Kim said the volume of sites opened by western small- and medium-sized biotech companies in South Korea has increased by 17% over the last 12 months – “showing a greater interest from North American and European companies.”

“The region is changing rapidly and the outcome of clinical trials strongly relies on how the study in managed operationally by the CRO and which investigators are involved in the trial,”​ Kim told us.

According to a report published by Frost & Sullivan​, the Asia Pacific CRO market is estimated to grow at a compound annual growth rate (CAGR) of 19.9%in 2020, as opposed a 10.4% CAGR expected in North America.

The report cited three key factors make Asia a preferred destination for clinical trials: speed, worldwide data acceptability, and cost-effectiveness.

Novotech has been present in South Korea since 2007 and completed 10 MFDS inspections with no major findings. It has 11 offices across the Asia-Pacific region.

The company in April of last year signed a memorandum of understanding​ (MOU) with the Asan Medical Center (AMC) Clinical Trial Center, which it has worked with since opening its operation in the country. The MOU formalized the company’s relationship with the center and its principal investigators.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more